Bionomics Inc.

Gabriel Kremmidiotis

Bernard Luke Flynn

Damian Wojciech Grobelny

Jason Hugh Chaplin

Gurmit Singh Gill

Annabell Francis Leske

Anthony Bais

Marina Kochetkova

Joanna Crawford

Alison Gardner

David Frederick Callen

Jason Powell

Tina Lavranos

Gurmit Sing Gill

Tina Christine Lavranos

Darcy Bates

Alan R Eastman

David Bibby

Annabell Frances Leske

Thomas John Gonda

Anthony John Bais

Jason Anthony Powell

Alison Elaine Gardner

Daniel J Inglis

Tina C Lavranos

Daniel Inglis

The present disclosure relates to the biological markers SAP, SHBG, Myoglobin, MMP-9, and SCF that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.

Predictive biomarkers

The present disclosure relates to the biological markers Ferritin and IL-8 that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.

Predictive baseline biomarkers for use of vascular disrupting agents

The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerization inhibitors.

Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors

The present disclosure provides a combination and a method for treating chronic lymphocytic leukemia (CLL).

Combination treatment protocol

A pharmaceutical composition of a tubulin polymerisation inhibitor and an mTOR inhibitor and a method of treating proliferative disease with a combination of a tubulin polymerisation inhibitor and an mTOR inhibitor.

Combination therapy for treating proliferative diseases

The presently disclosed subject matter relates to the identification of markers of endothelial cells which are in a quiescent or activated state, and more specifically to beta tubulin isotypes as markers which are differentially expressed between endothelial cells in these states. The beta tubulin isotypes can be used for the identification of candidate agents which selectively bind quiescent or activated endothelial cells, and to identify candidate agents which inhibit or promote angiogenesis and/or vascular function.

Methods of identifying agents that inhibit angiogenesis

Short interfering RNA (siRNA) molecules which modulate the expression of an angiogenesis-related gene by RNA interference are described. Short hairpin RNA (shRNA) molecules comprising said siRNA molecules are also described. These molecules can target all, or specific, isoforms of the gene. The use of these molecules and of isoforms of the gene for the treatment and diagnosis of angiogenesis-related disorders is also described.

Compositions and methods for angiogenesis-related molecules and treatments

An isolated nucleic acid molecule mapping to chromosome 16q24.3 and comprising the nucleotide sequence set forth in SEQ ID Numbers: 1 or 3.

Gene BNO1 mapping to chromosome 16q24.3

Gene BN01 mapping to chromosome 16q24.3

Growing community of inventors

Flagstaff Hill, Australia

Gabriel Kremmidiotis